Possible involvement of altered arginase activity, arginase type I and type II expressions, and nitric oxide production in occurrence of intimal hyperplasia in premenopausal human uterine arteries

Journal of Pharmacological Sciences

Volumn 106, Issue 3, 2008, Pages 385-393

  Marinova, Galina Vasileva ^a   Loyaga Rendon, Renzo Ygor ^b   Obayashi, Satoshi ^a   Ishibashi, Tomoko ^a   Kubota, Toshiro ^a   Imamura, Masatoshi ^a   Azuma, Hiroshi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Arginase I and II; Cyclic GMP; Human uterine artery; Intimal hyperplasia; Nitric oxide

Indexed keywords

ARGINASE; ARGINASE 1; ARGINASE II; CYCLIC GMP; NITRIC OXIDE; UNCLASSIFIED DRUG;

ABDOMINAL HYSTERECTOMY; ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE COURSE; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERPLASIA; INFORMED CONSENT; INTIMA; INTIMAL HYPERPLASIA; PREMENOPAUSE; SMOOTH MUSCLE; UPREGULATION; UTERINE ARTERY;

EID: 41549123593     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0072275     Document Type: Article

References (39)

1. Brown SA, Hutchinson R, Morrisett J, Boerwinkle E, Davis CE, Gotto AM, et al. Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb. 1993;13:1139-1158.
2. Newnham HH. Oestrogens and atherosclerotic vascular disease-lipid factors. Baillieres Clin Endocrinol Metab. 1993;7:61-93.
3. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
4. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291: 1701-1712.
5. Azuma H, Obayashi S, Hamasaki H, Koyama T, Aso T. Role of endothelium in the human uterine arteries during normal menstrual cycle. Br J Pharmacol. 1995;114:902-908.
6. Furchgott RF. Role of endothelium in responses of vascular smooth muscle. Circ Res. 1983;53:557-573.
7. Azuma H, Ishikawa M, Sekizaki S. Endothelium-dependent inhibition of platelet aggregation. Br J Pharmacol. 1986;88:411-415.
8. Lefer AM. Nitric oxide: Nature's naturally occurring leukocyte inhibitor. Circulation. 1997;95:553-554.
9. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83:1774-1777.
10. Ignarro LJ, Buga GM, Wei LH, Bauer PM, Wu GY, del Soldato P, et al. Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Sci U S A. 2001;98:4202-4208.
11. Boulanger C, Luscher TF. Release of endothelin from the porcine aorta: inhibition by endothelium-derived nitric oxide. J Clin Invest. 1990;85:587-590.
12. Lefer AM, Ma XL. Decreased basal nitric oxide release in hypercholesterolemia increases neutrophil adherence to rabbit coronary artery endothelium. Arterioscler Thromb. 1993;13: 771-776.
13. Cooke JP. Role of nitric oxide in progression and regression of atherosclerosis. West J Med. 1996;164:419-424.
14. Zhang C, Hein TW, Wang W, Chang CI, Kuo L. Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function. FASEB J. 2001;15:1264-1266.
15. Chicoine LG, Paffett ML, Young TL, Nelin LD. Arginase inhibition increases nitric oxide production in bovine pulmonary arterial endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2004;287:L60-L68.
16. Wei LH, Jacobs AT, Morris SM Jr, Ignarro LJ. IL-4 and IL-13 upregulate arginase I expression by cAMP and JAK/STAT6 pathways in vascular smooth muscle cells. Am J Physiol Cell Physiol. 2000;279:C248-C256.
17. Mori M, Gotoh T. Regulation of nitric oxide production by arginine metabolic enzymes. Biochem Biophys Res Commun. 2000;275:715-719.
18. Sasaki A, Doi S, Mizutani S, Azuma H. Roles of accumulated endogenous nitric oxide synthase inhibitors, enhanced arginase activity, and attenuated nitric oxide synthase activity in endothelial cells for pulmonary hypertension in rats. Am J Physiol Lung Cell Mol Physiol. 2007;292:L1480-L1487.
19. Loyaga-Rendon RY, Sakamoto S, Beppu M, Aso T, Ishizaka M, Takahashi R, et al. Accumulated endogenous nitric oxide synthase inhibitors, enhanced arginase activity, attenuated dimethylarginine dimethylaminohydrolase activity and intimal hyperplasia in premenopausal human uterine arteries. Atherosclerosis. 2005;178:231-239.
20. Sakai Y, Masuda H, Kihara K, Kurosaki E, Yamauchi Y, Azuma H. Involvement of increased arginase activity in impaired cavernous relaxation with aging in the rabbit. J Urol. 2004; 172:369-373.
21. Numao N, Masuda H, Sakai Y, Okada Y, Kihara K, Azuma H. Roles of attenuated neuronal nitric-oxide synthase protein expression and accelerated arginase activity in impairing neurogenic relaxation of corpus cavernosum in aged rabbits. BJU Int. 2007;99:1495-1499.
22. Imamura M, Waseda Y, Marinova GV, Ishibashi T, Obayashi S, Sasaki A, et al. Alterations of NOS, arginase, and DDAH protein expression in rabbit cavernous tissue after administration of cigarette smoke extract. Am J Physiol Regul Integr Comp Physiol. 2007;293:R2081-R2089.
23. Obayashi S, Aso T, Sato J, Hamasaki H, Azuma H. Intimal hyperplasia in human uterine arteries accompanied by impaired synergism between prostaglandin I2 and nitric oxide. Br J Pharmacol. 1996;119:1072-1078.
24. Obayashi S, Beppu M, Aso T, Goto M, Azuma H. 17 Beta-estradiol increases nitric oxide and prostaglandin I2 production by cultured human uterine arteries only in histologically normal specimens. J Cardiovasc Pharmacol. 2001;38:240-249.
25. Beppu M, Obayashi S, Aso T, Goto M, Azuma H. Endogenous nitric oxide synthase inhibitors in endothelial cells, endothelin-1 within the vessel wall, and intimal hyperplasia in perimenopausal human uterine arteries. J Cardiovasc Pharmacol. 2002;39:192-200.
26. Durante W, Liao L, Peyton KJ, Schafer AI. Lysophosphatidylcholine regulates cationic amino acid transport and metabolism in vascular smooth muscle cells. Role in polyamine biosynthesis. J Biol Chem. 1997;272:30154-30159.
27. Buga GM, Singh R, Pervin S, Rogers NE, Schmitz DA, Jenkinson CP, et al. Arginase activity in endothelial cells: inhibition by NG-hydroxy-L-arginine during high-output NO production. Am J Physiol. 1996;40:H1988-H1998.
28. Custot J, Moali C, Brollo M, Boucher JL, Delaforge M, Mansuy D, et al. The new alpha-amino acid N-omega-hydroxy-nor-Larginine: A high-affinity inhibitor of arginase well adapted to bind to its manganese cluster. J Am Chem Soc. 1997;119:4086-4087.
29. Moali C, Boucher JL, Sari MA, Stuehr DJ, Mansuy D. Substrate specificity of NO synthases: Detailed comparison of L-arginine, homo-L-arginine, their N-omega-hydroxy derivatives, and N-omega-hydroxynor-L-arginine. Biochemistry. 1998;37:10453-10460.
30. Napoli C, Ignarro LJ. Nitric oxide and atherosclerosis. Nitric Oxide. 2001;5:88-97.
31. Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol. 1990;30: 535-560.
32. Chinkers M, Garbers DL. Signal transduction by guanylyl cyclases. Annu Rev Biochem. 1991;60:553-575.
33. Blantz RC, Satriano J, Gabbai F, Kelly C. Biological effects of arginine metabolites. Acta Physiol Scand. 2000;168:21-25.
34. Jenkinson CP, Grody WW, Cederbaum SD. Comparative properties of arginases. Comp Biochem Physiol B Biochem Mol Biol. 1996;114:107-132.
35. Xu W, Kaneko FT, Zheng S, Comhair SAA, Janocha AJ, Goggans T, et al. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J. 2004;18:1746-1748.
36. Tabor CW, Tabor H. Polyamines. Ann Rev Biochem. 1984;53: 749-790.
37. Kepka-Lenhart D, Mistry SK, Wu GY, Morris SM Jr. Arginase I: a limiting factor for nitric oxide and polyamine synthesis by activated macrophages? Am J Physiol Regul Integr Comp Physiol. 2000;279:R2237-R2242.
38. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54-61.
39. McVary KT, Carrier S, Wessells H, Subcommittee on Smoking and Erectile Dysfunction Socioeconomic Committee, Sexual Medicine Society of North America. Smoking and erectile dysfunction: evidence based analysis. J Urol. 2001;166:1624-1632.